Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05634291 · ClinicalTrials.gov registry record · NA

Effects of the Nottingham Augmented Reality (AR) App for Arthritis Hand Joint Pain

A NA study of Chronic Pain and Opioid Use, sponsored by VRx Medical.

Completed
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT05634291: Completed NA study of Chronic Pain and Opioid Use, sponsored by VRx Medical.

NCT05634291 is a NA study of Chronic Pain and Opioid Use that has completed, run by VRx Medical. The registered enrollment target is 36 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05634291, a NA study of Chronic Pain and Opioid Use, has completed, sponsored by VRx Medical.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The aim of this run-in design, feasibility study is to assess outcomes (including opioid-use, pain intensity, emotional function, and general physical function) for an augmented reality illusion therapy in participants with chronic hand joint pain due to arthritis.

Primary Outcome

PEG is a three-Item scale assessing pain intensity and interference. Scale is from 0 (no pain) to 10 (pain as bad as you can imagine).

Interventions

  • OTHER Standard of care
  • DEVICE Nottingham AR smartphone app with active intervention

Study Locations (1)

California

  • VA San Diego Healthcare System - San Diego

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2022-06-13
Est. Completion 2023-07-21
Phase NA
VRx Medical

1 total trials

What the finished NCT05634291 record still lists

NCT05634291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.

NCT05634291 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05634291 about?

NCT05634291 is a clinical study titled "Effects of the Nottingham Augmented Reality (AR) App for Arthritis Hand Joint Pain". The aim of this run-in design, feasibility study is to assess outcomes (including opioid-use, pain intensity, emotional function, and general physical function) for an augmented reality illusion therapy in participants with chronic hand joint pain due to arthritis.

What is the current status of trial NCT05634291?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2022-06-13. Estimated completion is 2023-07-21.

What conditions does trial NCT05634291 study?

This clinical trial studies the following conditions: Chronic Pain, Opioid Use, Arthritis Hand.

What interventions are being tested in trial NCT05634291?

The interventions under investigation include: Standard of care (OTHER), Nottingham AR smartphone app with active intervention (DEVICE).

Who is sponsoring clinical trial NCT05634291?

This trial is sponsored by VRx Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05634291 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05634291's enrollment target sits among peer trials

36 228th of 301 higher than 72 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05634291, the US trial registry maintained by the National Library of Medicine. NCT05634291 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.